Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Saint-Herblain – page 17

606 clinical trials in Saint-Herblain, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Saint-Herblain at a glance
606
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

606 trials in Saint-Herblain

Open in trial search

Renal cell carcinoma

Recruiting

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Institut Gustave Roussy

Breast cancer

Recruiting

Study of Tuvusertib and Fulvestrant for Advanced Breast Cancer Resistant to CDK4/6 and Aromatase Inhibitors in Hormone Receptor-Positive, HER2-Negative Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Institut Paoli-Calmettes

Neuroendocrine tumour

Recruiting

Study on Retreatment with Lutetium (177Lu) Oxodotreotide for Patients with Intestinal Neuroendocrine Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:L-Arginine Hydrochloride
  • Sponsor:Institut Regional Du Cancer De Montpellier

Neoplasm+5

Recruiting

Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Recruiting

Study of Amivantamab, Lazertinib, and Pemetrexed for Patients with Advanced or Metastatic Solid Tumors, Including EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Endometrial cancer+4

Recruiting

Study of PC14586 for Patients with Advanced Solid Tumors with a Specific TP53 Mutation

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pc14586
  • Sponsor:Pmv Pharmaceuticals Inc.

Relapsing multiple sclerosis+2

Recruiting

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Teriflunomide
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Peritoneal sarcoma+5

Recruiting

Study on Adjusting Chemotherapy with Carboplatin and Paclitaxel for Patients with Poor Prognostic Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Arcagy Gineco

Penile cancer

Recruiting

Study on the Effects of Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin for Patients with Squamous Cell Carcinoma of the Penis and Lymph Node Metastasis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Unicancer

Rectal cancer

Recruiting

Study comparing preoperative drug combination with irinotecan, fluorouracil, calcium folinate and oxaliplatin for patients with locally advanced resectable rectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Assistance Publique Hopitaux De Paris

Bladder cancer

Recruiting

Study of Atezolizumab After Chemo-radiotherapy for Patients with Muscle-invasive Bladder Cancer Not Eligible for Radical Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Unicancer

Prostate cancer

Recruiting

Study on Darolutamide and Triptorelin for Patients with Localized High-Risk Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Unicancer

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Saint-Herblain

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for breast cancer, lung cancer, and gastric cancer. Research includes novel therapeutic approaches targeting specific cancer types.

  • Triple-negative breast cancer interventions
  • Non-small cell lung cancer therapies
  • Gastrointestinal cancer treatments

Several trials are evaluating new antibody-drug conjugates and combination therapies for metastatic diseases.

02 Neurological Disorders

Studies targeting various neurological conditions, with emphasis on frontotemporal dementia and multiple sclerosis. Research focuses on innovative therapeutic approaches and disease-modifying treatments.

  • Dementia progression studies
  • Multiple sclerosis treatments
  • Sleep disorder interventions

Trials include evaluation of novel antibodies and assessment of long-term treatment efficacy.

03 Cardiovascular Studies

Comprehensive research into heart failure prevention, pulmonary hypertension, and cardiac rhythm disorders. Studies focus on innovative therapeutic approaches and preventive measures.

  • Heart failure prevention strategies
  • Pulmonary hypertension treatments
  • Cardiac rhythm management

Research includes long-term safety assessments and combination therapy evaluations.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.